The Bone Microenvironment: a Fertile Soil for Tumor Growth

Current Osteoporosis Reports

Volumn 14, Issue 4, 2016, Pages 151-158

  Buenrostro, Denise ^a,b,c   Mulcrone, Patrick L ^b,c   Owens, Philip ^c   Sterling, Julie A ^a,b,c  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bisphosphonates; Bone microenvironment; Immune cells; Nervous system; Tumor induced bone disease; Vasculature

Indexed keywords

COLONY STIMULATING FACTOR 1; MATRIX METALLOPROTEINASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; RANTES; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; THROMBOSPONDIN 1;

ADRENERGIC SYSTEM; B LYMPHOCYTE; BONE DEVELOPMENT; BONE METASTASIS; BONE PAIN; CELL ACTIVITY; CELL DIFFERENTIATION; CELL INTERACTION; FIBROBLAST; IMMUNOCOMPETENT CELL; MACROPHAGE; METASTASIS ASSOCIATED MACROPHAGE; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOCYTE; OSTEOLYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; BONE; BONE MARROW; BONE MARROW CELL; BONE TUMOR; CYTOLOGY; HUMAN; METABOLISM; MYELOID-DERIVED SUPPRESSOR CELL; SECONDARY; VASCULARIZATION;

B-LYMPHOCYTES; BONE AND BONES; BONE MARROW; BONE MARROW CELLS; BONE NEOPLASMS; CELLULAR MICROENVIRONMENT; FIBROBLASTS; HUMANS; KILLER CELLS, NATURAL; MACROPHAGES; MYELOID-DERIVED SUPPRESSOR CELLS; OSTEOBLASTS; OSTEOCLASTS; OSTEOCYTES; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84977079202     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-016-0315-2     Document Type: Review

References (98)

1. Jemal A et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
2. Yoneda T, Sasaki A, Mundy GR. Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat. 1994;32(1):73–84.
3. Guise TA, Mundy GR. Cancer and bone. Endocr Rev. 1998;19(1):18–54.
4. Johnson RW et al. TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical hedgehog signaling. Cancer Res. 2011;71(3):822–31.
5. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2(8):584–93.
6. Coleman R et al. Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2014;25 Suppl 3:iii 124-37.
7. Coleman R et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol. 2014;15(9):997–1006.
8. Holen I, Coleman RE. Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Res. 2010;12(6):214.
9. Russell RG. Bisphosphonates: the first 40 years. Bone. 2011;49(1):2–19.
10. Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48(4):677–92.
11. Kostic A, Lynch CD, Sheetz MP. Differential matrix rigidity response in breast cancer cell lines correlates with the tissue tropism. PLoS One. 2009;4(7):e6361.
12. Provenzano PP et al. Matrix density-induced mechanoregulation of breast cell phenotype, signaling, and gene expression through a FAK-ERK linkage. Oncogene. 2009;28(49):4326–43.
13. Page JM et al. Matrix rigidity regulates the transition of tumor cells to a bone-destructive phenotype through integrin beta3 and TGF-beta receptor type II. Biomaterials. 2015;64:33–44. This paper demonstrated that the rigid mineralized bone matrix can alter gene expression and bone destruction in an integrin beta 3-TGF-β dependent manner.
14. Ruppender NS et al. Matrix rigidity induces osteolytic gene expression of metastatic breast cancer cells. PLoS One. 2010;5(11):e15451.
15. Johnson RW et al. Wnt signaling induces gene expression of factors associated with bone destruction in lung and breast cancer. Clin Exp Metastasis. 2014.
16. Guo R et al. A transient cell-shielding method for viable MSC delivery within hydrophobic scaffolds polymerized in situ. Biomaterials. 2015;54:21–33.
17. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011;11(6):411–25.
18. Guise TA et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest. 1996;98(7):1544–9.
19. Wang H et al. The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell. 2015;27(2):193–210.
20. Schneider A et al. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology. 2005;146(4):1727–36.
21. Taichman RS et al. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002;62(6):1832–7.
22. Sun X et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 2010;29(4):709–22.
23. Jung Y et al. Annexin II expressed by osteoblasts and endothelial cells regulates stem cell adhesion, homing, and engraftment following transplantation. Blood. 2007;110(1):82–90.
24. Jung Y et al. Prevalence of prostate cancer metastases after intravenous inoculation provides clues into the molecular basis of dormancy in the bone marrow microenvironment. Neoplasia. 2012;14(5):429–39.
25. Jung Y et al. Annexin 2 is a regulator of SDF-1/CXCL12 function in the hematopoietic stem cell endosteal niche. Exp Hematol. 2011;39(2):151–166.e1.
26. Park, SI et al. Parathyroid hormone-related protein drives a CD11b(+)Gr1(+) cell-mediated positive feedback loop to support prostate cancer growth. Cancer Res, 2013; 73(22), doi:10.1158/0008-5472.CAN-12-4692.
27. Akeno N et al. Induction of vascular endothelial growth factor by IGF-I in osteoblast-like cells is mediated by the PI3K signaling pathway through the hypoxia-inducible factor-2alpha. Endocrinology. 2002;143(2):420–5.
28. Kim JM et al. DJ-1 promotes angiogenesis and osteogenesis by activating FGF receptor-1 signaling. Nat Commun. 2012;3:1296.
29. Boyce BF, Schwarz EM, Xing L. Osteoclast precursors: cytokine-stimulated immunomodulators of inflammatory bone disease. Curr Opin Rheumatol. 2006;18(4):427–32. doi:10.1097/01.bor.0000231913.32364.32.
30. Glass 2nd DA et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8(5):751–64.
31. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655–64.
32. Crockett JC et al. Bone remodelling at a glance. J Cell Sci. 2011;124(7):991–8.
33. Hirbe AC et al. Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone. Proc Natl Acad Sci U S A. 2007;104(35):14062–7.
34. Zhou JZ et al. Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis. Oncogene. 2015;34(14):1831–42.
35. Sottnik JL et al. Tumor-induced pressure in the bone microenvironment causes osteocytes to promote the growth of prostate cancer bone metastases. Cancer Res. 2015;75(11):2151–8. This paper presents data identifying the contribution of physical forces to tumor cell growth and that osteocytes play an important role as mediators in the bone metastatic niche.
36. Delgado-Calle J et al. Bidirectional notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma. Cancer Res. 2016;76(5):1089–100.
37. Augsten M. Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment. Front Oncol. 2014;4:62.
38. Duda DG et al. Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci U S A. 2010;107(50):21677–82.
39. Calvo F et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol. 2013;15(6):637–46.
40. Harper J, Sainson RC. Regulation of the anti-tumour immune response by cancer-associated fibroblasts. Semin Cancer Biol. 2014;25:69–77.
41. Kraman M et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-α. Science. 2010;330(6005):827–30.
42. Bergfeld SA, DeClerck YA. Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev. 2010;29(2):249–61.
43. Quante M et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell. 2011;19(2):257–72.
44. Bergfeld SA, Blavier L, DeClerck YA. Bone marrow-derived mesenchymal stromal cells promote survival and drug resistance in tumor cells. Mol Cancer Ther. 2014;13(4):962–75.
45. Wu HC et al. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer. 1994;57(3):406–12.
46. Li X et al. Loss of TGF-beta responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions. Mol Cancer Res. 2012;10(4):494–503.
47. Nakamura R et al. Transforming growth factor-beta synthesized by stromal cells and cancer cells participates in bone resorption induced by oral squamous cell carcinoma. Biochem Biophys Res Commun. 2015;458(4):777–82.
48. Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol. 2009;9(4):259–70.
49. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66(2):605–12.
50. Deng L et al. A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis. Am J Pathol. 2010;176(2):952–67.
51. Pollard JW. Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol. 2008;84(3):623–30.
52. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.
53. Biswas SK et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood. 2006;107(5):2112–22.
54. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39–51.
55. Chang MK et al. Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo. J Immunol. 2008;181(2):1232–44.
56. Winkler IG et al. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood. 2010;116(23):4815–28.
57. Alexander KA et al. Osteal macrophages promote in vivo intramembranous bone healing in a mouse tibial injury model. J Bone Miner Res. 2011;26(7):1517–32.
58. Buenrostro D, Park SI, Sterling JA. Dissecting the role of bone marrow stromal cells on bone metastases. Biomed Res Int. 2014;2014:875305.
59. Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest. 2015;125(9):3356–64. This paper reviews controversial issues in myeloid-derived suppressor cell biology, including their role in cancer progression and metastasis. This review also emphasis how these cells may be used both as prognostic factors and as therapeutic targets.
60. Youn JI et al. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 2008;181(8):5791–802.
61. Movahedi K et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008;111(8):4233–44.
62. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006;66(2):1123–31.
63. Elkabets M et al. IL-1beta regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur J Immunol. 2010;40(12):3347–57.
64. Srivastava MK et al. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 2010;70(1):68–77.
65. Lindau D et al. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 2013;138(2):105–15.
66. + cell-mediated positive feedback loop to support prostate cancer growth. Cancer Res. 2013;73(22):6574–83.
67. Danilin S et al. Myeloid-derived suppressor cells expand during breast cancer progression and promote tumor-induced bone destruction. Oncoimmunology. 2012;1(9):1484–94.
68. Sawant A et al. Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer. Cancer Res. 2013;73(2):672–82. This paper identified myeloid-derived suppressor cells as a novel osteoclast progenitor that had the potential to stimulate bone metastasis during cancer progression.
69. Vivier E et al. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol. 2012;12(4):239–52.
70. Diefenbach A et al. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 2001;413(6852):165–71.
71. Liu G et al. Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis. J Clin Invest. 2013;123(10):4410–22.
72. Zitvogel L, Kroemer G. Cancer: antibodies regulate antitumour immunity. Nature. 2015;521(7550):35–7.
73. Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell. 2005;8(5):369–80.
74. Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity. 2009;30(5):636–45.
75. Rajewsky K. Clonal selection and learning in the antibody system. Nature. 1996;381(6585):751–8.
76. Balkwill F, Montfort A, Capasso M. B regulatory cells in cancer. Trends Immunol. 2013;34(4):169–73.
77. Zhang K et al. CD8+ T cells regulate bone tumor burden independent of osteoclast resorption. Cancer Res. 2011;71(14):4799–808.
78. Monteiro AC et al. T cells induce pre-metastatic osteolytic disease and help bone metastases establishment in a mouse model of metastatic breast cancer. PLoS One. 2013;8(7):e68171.
79. Pasquier E et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget. 2011;2(10):797–809.
80. Ji Y et al. The role of β-adrenergic receptor signaling in the proliferation of hemangioma-derived endothelial cells. Cell Div. 2013;8:1–1.
81. Thaker PH et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006;12(8):939–44.
82. Thaker PH, Sood AK. The neuroendocrine impact of chronic stress on cancer. Semin Cancer Biol. 2008;18(3):164–70.
83. Chida Y et al. Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat Clin Pract Oncol. 2008;5(8):466–75.
84. Palesh O et al. Stress history and breast cancer recurrence. J Psychosom Res. 2007;63(3):233–9.
85. Melhem-Bertrandt A et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol. 2011;29(19):2645–52.
86. Elefteriou F et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature. 2005;434(7032):514–20.
87. Campbell JP et al. Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biol. 2012;10(7):e1001363.
88. Costa L et al. Impact of skeletal complications on patients’ quality of life, mobility, and functional independence. Support Care Cancer. 2008;16(8):879–89.
89. Käkönen S-M, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer. 2003;97(S3):834–9.
90. Clohisy DR and PW Mantyh. Bone cancer pain. Clin Orthop Relat Res, 2003, (415 Suppl): 279-88.
91. Halvorson KG et al. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res. 2005;65(20):9426–35.
92. Falk S et al. P2X7 receptor-mediated analgesia in cancer-induced bone pain. Neuroscience. 2015;291:93–105.
93. Ungard RG, Seidlitz EP, Singh G. Inhibition of breast cancer-cell glutamate release with sulfasalazine limits cancer-induced bone pain. Pain. 2014;155(1):28–36.
94. Smith MR et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012;379(9810):39–46.
95. Le Gall C et al. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res. 2007;67(20):9894–902.
96. Chavez-Macgregor M et al. Angiogenesis in the bone marrow of patients with breast cancer. Clin Cancer Res. 2005;11(15):5396–400.
97. Kopp H-G et al. The bone marrow vascular niche: home of HSC differentiation and mobilization. Physiology. 2005;20(5):349–56.
98. Ghajar CM et al. The perivascular niche regulates breast tumour dormancy. Nat Cell Biol. 2013;15(7):807–17. This paper provides evidence for a link between the vascular and tumor dormancy, a subject that had not been well studied.